Skip to main content
. 2020 Feb 24;11(2):53–73. doi: 10.5306/wjco.v11.i2.53

Table 1.

The World Health Organization, Response Evaluation Criteria in Solid Tumors version 1.0 and Response Evaluation Criteria in Solid Tumors version 1.1 criteria1

WHO RECIST v1.0 RECIST v1.1
Method Sum of products of two longest diameters in perpendicular dimensions (bidimensional; surface area) Sum of longest diameters of target lesions (unidimensional) Sum of longest diameters of non-nodal target lesions and short axis of nodal target lesions (unidimensional)
No. of measured lesion All lesions Target lesions: maximum 5 per organ, 10 in total Target lesions: Maximum 2 per organ, 5 in total
Response
CR Disappearance of all known disease, confirmed at 4 wk2 Disappearance of all known disease, confirmed at 4 wk Disappearance of all known disease, confirmed at 4 wk, lymph nodes must be < 10 mm short axis
PR ≥ 50% decrease from baseline, confirmed at 4 wk ≥ 30% decrease from baseline, confirmed at 4 wk ≥ 30% decrease from baseline, confirmed at 4 wk
SD Neither PR nor PD criteria met Neither PR nor PD criteria met Neither PR nor PD criteria met
PD ≥ 25% increase, no CR, PR, or SD, new lesion (s), ≥ 25% increase in 1 lesion ≥ 20% increase over smallest sum observed, no CR, PR, or SD, new lesion(s) ≥ 20% increase over smallest sum observed, no CR, PR, or SD, new lesion(s)3. The sum must also demonstrate an absolute increase of at least 5 mm
1

Modified from Choi et al[12], and extended with adding Response Evaluation Criteria in Solid Tumors version 1.1;

2

Minimum interval between baseline assessment and first response evaluation;

3

On detection of new lesions, fluorodeoxyglucose-positron emission tomography scan is included. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; WHO: World Health Organization; RECIST: Response Evaluation Criteria in Solid Tumors.